Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year. 

With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial. 

Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US. 

The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023. 

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.